

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Ophthalmology

ESPS manuscript NO: 15609

Title: New Treatments for Diabetic Macular Edema

Reviewer's code: 00505120

Reviewer's country: Italy

Science editor: Yue-Li Tian

Date sent for review: 2014-12-01 19:48

Date reviewed: 2014-12-15 18:35

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

I read with interest the manuscript entitled "New Treatments for Diabetic Macular Edema" by Zaidi and Ansari. The paper is well written and well structured. I suggest only to complete with some few additional paragraphs considering the use and the role of fluocinolone acetonide, pegaptanib, aflibercept, bevasiranib and rapamycin.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Ophthalmology

ESPS manuscript NO: 15609

Title: New Treatments for Diabetic Macular Edema

Reviewer's code: 00505061

Reviewer's country: Bulgaria

Science editor: Yue-Li Tian

Date sent for review: 2014-12-01 19:48

Date reviewed: 2014-12-13 23:07

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	PubMed Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Dear Authors, In the presented review article you give a concise and informative overview concerning the knowledge on current and modern medical treatment of diabetic macular edema (DME). The manuscript is concise and well structured. The language needs no revision. I would only add few remarks: 1) As the authors give no comments on the management of tractional DME, which requires surgical treatment, it might be appropriate to show in the title or the abstract that the review concerns only new medical treatment modalities for DME; 2) In the section "Anti-VEGF Agents" the authors may give some comments on the other 2 available anti-VEGF agents - pegaptanib sodium (Macugen) and the newest one - aflibercept (Eylea); 3) On p. 8, line 17 - it should be DME instead of DMO. Best regards, Reviewer